Study design	Author  (year)	Country	Patient selection	Sample size (per protocol pop.)	Length of follow‐up (days)	Trial sponsor	Baseline liver function tests?	Excluded participants with raised liver enzymes
Single arm	Bui 2020	Vietnam	Adults + children	155	42	BMG USAID	Yes	Yes
	Han 2020	Myanmar	Adults  + children (≥ 6 years)	390	42	BMG USAID	No	No
	Leang 2016	Cambodia	Adults + children	117	42	BMG	No	Yes
	Leang 2019a	Cambodia	Adults + children (≥ 7 years)	224	42	BMG USAID	No	Yes
	Leang 2019b	Cambodia	Adults + children (≥ 7 years)	121	42	BMG	No	Yes
Cohort event monitoring	Lutete 2021a	Cameroon, Democratic Republic of the Congo, Gabon, Côte D'Ivoire, Republic of the Congo	Adults + children	7746	28	MMV	Yes	No
Dose escalation	Ramharter 2008	Gabon	Children (2 to 14 years)	59	42	MMV Shin Poong Pharma	Yes	Yes
All studies used Pyramax as the study drug, which was supplied by Shin Poong Pharmaceuticals. All studies used a dose of 180 mg pyronaridine plus 60 mg artesunate, except Ramharter 2008, which was a dose‐escalation study using four doses: 48 mg of pyronaridine tetraphosphate and 16 mg of artesunate; 72 mg of pyronaridine tetraphosphate and 24 mg of artesunate; 96 mg of pyronaridine tetraphosphate and 32 mg of artesunate; 60 mg of pyronaridine tetraphosphate and 20 mg of artesunate. Abbreviations: BMG: Bill & Melinda Gates Foundation; MMV: Medicines for Malaria Venture.